Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3891-3900 Newer>

The Motley Fool July 23, 2007 Brian Lawler	A Setback for Elan and Biogen Elan and Biogen receive negative news about Tysabri. The EU medical authorities won't allow its use as a treatment for Crohn's disease.
The Motley Fool July 23, 2007 Brian Lawler	GPC's Date With the FDA A document released by the FDA outlines its concerns with GPC's lead drug. Investors, take note.
The Motley Fool July 23, 2007 Brian Lawler	Progenics Gets Back In the Game Being the first approved to market an oral compound to treat one of the more painful side effects from opioid use will be a boon to whichever drugmaker can reach this goal. With the competitior Adolor looking more likely to be out of this race, Progenics is in the pole position once again.
The Motley Fool July 23, 2007 Brian Lawler	Medarex Cheering for Its Partner The biopharma's partner advances one of its compounds into later stage clinical testing. Investors, take note.
The Motley Fool July 23, 2007 Ryan Fuhrmann	Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note.
The Motley Fool July 23, 2007 Brian Lawler	Acquisitive Ways Paying Off for Genzyme A recently acquired drug yields positive study results. Genzyme investors, take note.
BusinessWeek July 30, 2007 Arlene Weintraub	Is Merck's Medicine Working? Spurred by the Vioxx fiasco, CEO Clark is trying to revamp the drug giant's culture. Analysts expect Merck's top line to grow 4%, to $23.5 billion this year, an achievement considering that sales growth had flatlined even before Vioxx imploded.
BusinessWeek July 30, 2007	Another Risk Factor For Merck Plaintiffs' lawyers are salivating over evidence they hope could support their argument that even patients who used the painkiller for short periods were in danger.
BusinessWeek July 30, 2007 Gene G. Marcial	A Promising Pipeline At Pipex Little-known Pipex Pharmaceuticals may have a stable of winners in the making. Investors, take note.
The Motley Fool July 20, 2007 Billy Fisher	Sales Surge at Intuitive Surgical Huge demand for Intuitive Surgical's da Vinci robotic surgical system leads to an 84% increase in operating income and a huge jump in stock price.
<Older 3891-3900 Newer> Return to current articles.